pharmaphorum6d
Record Shingrix sales help GSK raise 2022 forecasts
GSK's HIV business, run through joint venture company ViiV Healthcare, also had a good quarter with sales up 14% to £1.4 billion, led by gains for two-drug oral regimens Dovato (dolutegravir ...
Yahoo Finance6d
ViiV Healthcare Announces Reimbursement for APRETUDE for HIV-1 Pre-Exposure Prophylaxis (PrEP) under the Non-Insured Health Benefits (NIHB) Program
Tharani Napper, Government Affairs & Market Access Director, ViiV Healthcare Canada: "We commend the NIHB Program for prioritizing improved access to new HIV prevention options for Indigenous ...
Yahoo Finance6d
ViiV Healthcare Announces Reimbursement for APRETUDE for HIV-1 Pre-Exposure Prophylaxis (PrEP) under the Non-Insured Health Benefits (NIHB) Program
Tharani Napper, Government Affairs & Market Access Director, ViiV Healthcare Canada: "We commend the NIHB Program for prioritizing improved access to new HIV prevention options for Indigenous ...
Finanznachrichten6d
ViiV Healthcare's APRETUDE Now Covered Under Canada's NIHB Program For HIV Prevention
LONDON (dpa-AFX) - ViiV Healthcare, a global specialist HIV company majority-owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, Wednesday announced that APRETUDE ...
pharmaphorum6d
ViiV claims $1.25bn settlement from Gilead in HIV patent dispute
A patent dispute between ViiV Healthcare and Gilead Sciences has been resolved, with Gilead agreeing to pay a $1.25 billion settlement as well as royalties on sales of one of its top HIV products.
BioSpace5d
ViiV Healthcare Announces Reimbursement for APRETUDE for HIV-1 Pre-Exposure Prophylaxis (PrEP) under the Non-Insured Health Benefits (NIHB) Program
MONTRÉAL, March 25, 2025 /CNW/ - ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce ...